LONDON, UK, Feb. 13 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS) (www.htdsmedical.com) has entered negotiations to merge with a health care UK based company that has developed a radically new product which is marketed in many European countries, and already has the FDA approval (or authority equivalent to the specific country). The product employs food grade ingredients that are FDA approved.
HTDS Andrea Zecevic-Rubio, Chief Project Scientist, Director, R&D, noted, "I'm speaking purely from a scientific and medical stance. This was an opportunity that came up earlier last month in my research. We immediately dispatched Company representatives to pursue negotiations on a corporate level. We are very encouraged by the results to date. We think this UK health care company has a tremendous upside as it truly is a new approach to the health care services they offer. Furthermore this company already sells their product in market, and given the fact that it is a drug-free approach it currently is made available in pharmacies and other similar type locations."
Negotiations are continuing in the U.K., and the Company hopes to make more definitive announcements on this matter by early March. The planned merger with Mellow Hope is unaffected by these recent events other than the fact that HTDS will become more of a medical conglomerate when both the UK and China mergers are complete. The UK company reports its revenues in Sterling and has gross revenue sales of about 2 million USD.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet http://www.pinksheets.com/ filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.
CONTACT: For scientific dialogue and inquiry only Andrea can be reached via e-mail at email@example.com; For any corporate matters the readers should contact the company directly at firstname.lastname@example.org
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved